News und Analysen
Voyageurs du Monde: Excellent first half performance
BILENDI: New record results in the first half of 2025 • Historic half-yearly EBITDA margin of 20.6 % (+1.9 pt) • Adjusted operating profit up +87 %
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF 2025
FIGEAC AÉRO: FIGEAC AÉRO NORTH AMERICA AWARDED NEW CONTRACT BY BOMBARDIER
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
FIGEAC AÉRO: FIGEAC AÉRO SECURES ITS LONG-TERM PARTNERSHIP WITH SAFRAN AIRCRAFT ENGINES
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
FIGEAC AÉRO: FURTHER PROGRESS IN AEROSPACE POWER GENERATION WITH SAFRAN ELECTRICAL & POWER
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
RTL Luxemburg erweitert den Einsatz von Verimatrix-Technologien zum Schutz hochwertiger Automobilrennen vor Piraterie
Verimatrix, (Euronext Paris: VMX), ein führender Anbieter von Sicherheitslösungen für eine sicherere vernetzte Welt, gab heute bekannt, dass RTL Luxemburg, das führende Medienunternehmen des
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy
Regulatory News:
Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media
ROCTOOL: Live at K-Show: Roctool Slashes Cycle Times in High-Heat Molding Demonstrations
Verimatrix und Velocix schließen sich zusammen, um CDN-Piraterie zu bekämpfen
Regulatorische Nachrichten:
Verimatrix, (Euronext Paris: VMX), der führende Anbieter von Lösungen für eine moderne, vernetzte Welt mit menschenorientierter Sicherheit, gab heute eine
Verimatrix and Velocix Team Up to Fight CDN Piracy
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced a strategic collaboration with Velocix, the
EQS-News: Abivax Presents First Half 2025 Financial Results
FIGEAC AÉRO: Q1 2025/26 REVENUE: €101.9m, 10.3% ORGANIC GROWTH 17th CONSECUTIVE QUARTER OF GROWTH
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Announces Its Participation In Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss